7,056 Shares in Illumina, Inc. $ILMN Purchased by Fairvoy Private Wealth LLC

Fairvoy Private Wealth LLC acquired a new position in Illumina, Inc. (NASDAQ:ILMN) in the third quarter, Holdings Channel.com reports. The institutional investor acquired 7,056 shares of the life sciences company’s stock, valued at approximately $1,931,000.

Other large investors have also recently added to or reduced their stakes in the company. Fiduciary Financial Advisors bought a new stake in Illumina during the 2nd quarter valued at $26,000. MCF Advisors LLC boosted its position in Illumina by 172.4% during the 2nd quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 100 shares during the period. Keating Financial Advisory Services Inc. acquired a new position in Illumina during the 2nd quarter worth $32,000. Rakuten Securities Inc. bought a new position in shares of Illumina in the second quarter worth $33,000. Finally, WealthCollab LLC grew its stake in shares of Illumina by 51.5% in the first quarter. WealthCollab LLC now owns 303 shares of the life sciences company’s stock worth $37,000 after purchasing an additional 103 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ILMN has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft lowered Illumina to a “hold” rating in a report on Wednesday, August 5th. Leerink Partners upped their price objective on shares of Illumina from $220.00 to $300.00 and gave the stock an “outperform” rating in a report on Tuesday, September 29th. Canaccord Genuity Group upped their price objective on shares of Illumina from $205.00 to $300.00 and gave the stock a “hold” rating in a report on Monday. Argus increased their target price on shares of Illumina from $180.00 to $235.00 and gave the company a “buy” rating in a research report on Thursday, September 3rd. Finally, JPMorgan Chase & Co. increased their target price on shares of Illumina from $220.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Ten analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Illumina currently has an average rating of “Hold” and an average target price of $231.88.

Insider Activity

In other news, Director Keith Meister sold 457,858 shares of the business’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total value of $91,617,385.80. Following the sale, the director owned 2,372,694 shares of the company’s stock, valued at approximately $474,776,069.40. The trade was a 16.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders sold 2,061,850 shares of company stock worth $436,479,102. 2.90% of the stock is currently owned by company insiders.

Illumina Price Performance

Shares of NASDAQ ILMN traded up $0.12 during mid-day trading on Monday, reaching $262.66. 1,902,458 shares of the company traded hands, compared to its average volume of 2,175,622. Illumina, Inc. has a fifty-two week low of $94.00 and a fifty-two week high of $309.35. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The firm has a market cap of $39.66 billion, a PE ratio of 49.00, a price-to-earnings-growth ratio of 3.72 and a beta of 1.41. The stock has a fifty day simple moving average of $234.53 and a 200-day simple moving average of $186.47.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

About Illumina

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.